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RHEUMATOID ARTHRITIS (RA) PATIENTS TREATED WITH
TOCILIZUMAB (TCZ): THE LITHE STUDY
R. Fleischmann1, R. Burgos-Vargas2, P. Ambs3, E. Alecock4 and
J. Kremer5
1Metroplex Clinical Research Center, Dallas, TX, USA; 2Hospital
General de Me´xico, Mexico City, Mexico; 3F. Hoffmann-La Roche,
Basel, Switzerland; 4F. Hoffmann-La Roche, Welwyn, UK; 5Albany
Medical Centre, Albany, NY, USA
Background: Patients with moderate to severe RA who remained on
methotrexate (MTX) despite inadequate response were treated with
TCZ in a double-blind, randomized, controlled phase 3 trial. Results of
a 2-year planned analysis from this study are presented.
Methods: Patients were randomized to treatment with TCZ 4 mg/
kgþMTX (TCZ4), TCZ 8 mg/kgþMTX (TCZ8) or placeboþMTX (CON)
every 4 weeks. If patients failed to respond (<20% improvement in
swollen and tender joint count; SJC and TJC) then stepwise rescue
therapy could begin at week 16. Patients with 70% improvement in
SJC and TJC could continue the blinded therapy at the end of year 1 to
week 104. For all other patients, open-label TCZ8 was initiated at week
52. Change from baseline in Genant-modified total Sharp score
(GmTSS) and physical function (AUC of change from baseline in HAQ-
DI) were the primary 2-year end points. Linear extrapolation (GmTSS)
or standardization (change in HAQ-DI) was used for missing data. The
impact of 2 years of treatment was examined by assessing efficacy
end points over time for patients randomized to TCZ8, with the last
observation carried forward for SJC and TJC in patients who received
rescue therapy or withdrew.
Results: The intention to treat population consisted of 398 TCZ8, 399
TCZ4 and 393 CON patients. At 2 years, exposure rates in patient-
years (PY) were 1320.0, 521.9 and 284.8 in TCZ8, TCZ4 and CON
patients, respectively. At year 2, patients in the TCZ8 group had 81%
less radiographic progression vs CON patients (based on linear
extrapolation of mean change in GmTSS). Significantly more TCZ8
patients had no radiographic progression vs CON patients
(P 0.0001). AUC of change from baseline in HAQ-DI showed
significant improvement in physical function in TCZ4 and in TCZ8 vs
CON patients (P 0.0025). In patients initially randomized to TCZ8, a
low disease activity score (LDAS; DAS28 < 3.2) was seen in >60% of
patients and the DAS28 remission (DAS28 <2.6) rate was 48% at
week 52 and continued to increase to week 104. By week 52, patients
treated with TCZ8 had clinically significant improvements in SJC that
were maintained through week 104. Rates per 100 PY for adverse
events (AEs) were higher in TCZ8 and TCZ4 (263.6, 275.4) vs CON
patients (251.4) while rates for serious AEs were comparable (11.4,
12.1, 10.9, respectively). Rates per 100 PY of AEs leading to
withdrawal (7.4, 32.5, 4.8) and treatment modification (8.4, 30.7,
20.4) were higher in TCZ8 and TCZ4 vs CON patients, respectively and
death rates were comparable (0.6, 0.2, 0.4).
Conclusions: Treatment with TCZþMTX inhibits radiographic pro-
gression over 2 years and improves physical function as shown by
DAS28 remission, LDAS and low SJC, with a manageable safety profile.
Disclosure statement: E.A., F. Hoffmann-La Roche - Employee. P.A.,
F. Hoffmann-La Roche - Employee. R.B.-V., F. Hoffmann-La Roche -
Honoraria. R.F., Genentech - Research Funding, Honoraria. J.K., F.
Hoffmann-La Roche - Research funding, Honoraria.
OP5. BENEFIT OF CONCOMITANT DMARD USE ON THE
PERSISTENCE WITH ANTI-TNF THERAPIES IN RHEUMATOID
ARTHRITIS: RESULTS FROM THE BRITISH SOCIETY OF
RHEUMATOLOGY BIOLOGICS REGISTER (BSRBR)
Moetaza M. Soliman1, Darren M. Ashcroft1, Kath D. Watson2,
Mark Lunt2, Deborah P. Symmons2, Kimme L. Hyrich2, on behalf of
the BSR Biologics Register3
1School of Pharmacy and Pharmaceutical Sciences, The University
of Manchester, Manchester, UK; 2arc Epidemiology Unit, The
University of Manchester, Manchester, UK; 3British Society for
Rheumatology, London, UK
Background: Increasingly, one or more disease modifying anti-
rheumatic drugs (DMARDs) other than methotrexate (MTX) are being
used with anti-tumour necrosis factor (anti-TNF) therapies in rheuma-
toid arthritis (RA). The effect of these alternative concomitant therapies
on anti-TNF treatment persistence remains relatively unknown. This
study aimed to evaluate the effect of different concomitant DMARDs
on the persistence with anti-TNF therapies in RA.
Methods: This analysis included 10396 patients with RA registered
with the BSRBR who were starting their first anti-TNF therapy
(etanercept (n¼3605), infliximab (n¼ 3136) or adalimumab
(n¼ 3655)) and were receiving one of the following DMARD/combina-
tions: No DMARD (n¼3339), MTX (n¼4418), leflunomide (LEF)
(n¼ 610), sulphasalazine (SSZ) (n¼308), MTXþSSZ (n¼902),
MTXþ hydroxychloroquine (HCQ) (n¼ 401) or MTXþSSZþHCQ
(n¼ 418). Kaplan–Meier survival analysis was used to study the
persistence with anti-TNF therapy in each DMARD subgroup out to
5 years. Patients were censored at the time their first anti-TNF was
discontinued, at the last known follow-up, or death, whichever came
first. Multivariate Cox proportional hazard models, adjusted for
baseline age, gender, DAS28, HAQ, anti-TNF therapy and previous
DMARD history, were used to compare treatment persistence overall
and according to the reason of discontinuation (inefficacy or adverse
events) between each of the DMARD subgroups, using MTX as the
reference group.
Results: One-year drug survival (95% CIs) of the first anti-TNF
therapy was 71% (71:72) but this dropped to only 42% (41:43) at
5 years. Compared with MTX, patients receiving no DMARD, LEF
or SSZ were more likely to discontinue their first anti-TNF therapy
while patients receiving MTX in combination with other DMARDs
showed superior treatment persistence. These associations
remained when the results were restricted to the reason for stopping
(inefficacy or adverse events) and when stratified by anti-TNF therapy
(Table).
Conclusions: The use of concomitant DMARDs with anti-TNF
therapies in RA significantly improves treatment persistence, with the
best drug survival seen in those receiving combination therapies.
These results would support the continued use of background DMARD
therapy combinations which include MTX. Consideration should be
given to the discontinuation of LEF and SSZ monotherapy at the time
anti-TNF therapies are commenced.
Disclosure statement: BSRBR, Wyeth - Research Grant, Schering-
Plough - Research Grant, Abbott - Research Grant, Biovitrum -
Risk of Anti-TNF discontinuation
DMARD
Co-therapy
Adjusted Hazard Ratios of the multivariate analysis (95% CIs) P< 0.05
All Stops Stopping for Inefficacy Stopping for Adverse Events All Stops - Etanercept All Stops - Infliximab All Stops - Adalimumab
MTX Reference
None 1.40 (1.30:1.51) 1.34 (1.20:1.51) 1.47 (1.30:1.65) 1.27 (1.12:1.45) 1.39 (1.18:1.63) 1.42 (1.25:1.61)
SSZ 1.23 (1.03:1.47) 1.34 (1.04:1.74) 1.21 (0.91:1.60) 0.89 (0.64:1.24) 1.42 (0.92:2.19) 1.41 (1.11:1.80)
LEF 1.41 (1.25:1.59) 1.58 (1.32:1.88) 1.34 (1.10:1.62) 1.27 (1.02:1.57) 1.79 (1.43:2.26) 1.31 (1.07:1.60)
MTX-SSZ 0.76 (0.67:0.86) 0.77 (0.64:0.92) 0.70 (0.57:0.86) 0.64 (0.49:0.85) 0.87 (0.73:1.04) 0.72 (0.57:0.90)
MTX-HCQ 0.81 (0.68:0.96) 0.83 (0.64:1.06) 0.85 (0.66:1.11) 0.97 (0.68:1.37) 0.76 (0.58:0.98) 0.77 (0.58:1.03)
MTX-SSZ-HCQ 0.80 (0.68:0.95) 0.75 (0.58:0.96) 0.87 (0.67:1.13) 0.93 (0.64:1.35) 0.75 (0.59:0.96) 0.79 (0.60:1.05)
Research Grant, Roche - Research Grant. All other authors have
declared no conflicts of interest.
OP6. RITUXIMAB PLUS METHOTREXATE (MTX) INHIBITS
JOINT DAMAGE AND IMPROVES CLINICAL OUTCOMES IN
PATIENTS WITH EARLY, ACTIVE RHEUMATOID ARTHRITIS
(RA) WHO ARE NAI¨VE TO MTX
Paul P. Tak1, William Rigby2, Andrea Rubbert3, Charles Peterfy4,
Ronald F . van Vollenhoven5, William Stohl6, Eva Hessey7,
Annie Chen8, Helen Tyrrell7 and Tim Shaw7
1Academic Medical Centre/University of Amsterdam, Amsterdam,
Netherlands; 2Dartmouth Hitchcock Medical Center, Lebanon, OH;
3University of Cologne, Cologne, Germany; 4Synarc Inc., San
Francisco, CA, USA; 5Karolinska University Hospital, Stockholm,
Sweden; 6USC, Los Angeles, CA, USA; 7Roche Products Ltd, Welwyn
Garden City, UK; 8Genentech Inc, South San Francisco, CA, USA
Background: To assess the clinical and radiological benefit of addition
of rituximab to MTX in patients with early, active RA not previously
treated with MTX.
Methods: Patients with active RA (swollen and tender joint counts  8)
and naı¨ve to MTX were randomized to either placeboþMTX or
rituximab (2 500 mg or 21000 mg) þMTX. In all groups, MTX was
initiated at 7.5 mg/week and titrated to 20 mg/week by week 8.
Rituximab was given by IV infusion on days 1 and 15. From week 24,
patients received a second course of rituximab when DAS28 was
 2.6. Radiographs were taken at screening and at weeks 24 and 52
and were centrally read using the Genant-modified Sharp method
(mTSS; readers blinded to sequence and treatment). The primary
endpoint was change from screening in the mTSS at week 52.
Results: Of the 755 randomized patients, 715 were radiographically
evaluable. Groups were well matched at baseline with mean RA
duration of 0.9 years and DAS28 >7. Rituximab (21000 mg) þMTX
resulted in a significantly lower change in mTSS and significantly
higher proportion of patients with no joint progression compared with
placeboþMTX at 52 weeks (Table). Both doses of rituximab improved
clinical outcomes compared with MTX alone. Safety data were
consistent with those previously reported. Serious adverse events
occurred in 10% (placeboþMTX), 9% (rituximab 2 500 mgþMTX)
and 10% (rituximab 21000 mgþMTX) of patients. The rate of
serious infections was 6.09, 4.61 and 3.73 events/100 patient-years,
respectively. Three deaths occurred (pneumonia n¼2 and cerebral
infarct), which all occurred in the placeboþMTX group.
Conclusions: Rituximab (21000 mg)þMTX significantly improved
clinical outcomes (including major clinical response) and inhibited joint
damage, compared with MTX alone in patients with early, active
RA. Rituximab (2500 mg) improved clinical but not radiological
outcomes.
Disclosure statement: A.C., Genentech - Employment, Stocks or
Stock options, Roche - Stocks or Stock options. E.H., Roche -
Employment. C.P., Synarc Inc - Stock or stock options, Synarc Inc -
Employment, Synarc Inc - Ownership or partnership. W.R., Genentech
- Consulting fees, Speakers bureau, Biogen/IDEC - Consulting fees,
Speakers bureau. A.R., Roche - Consulting fees, Abbott - Consulting
fees, UCB - Consulting fees, Essex - Consulting fees, BMS - Consulting
fees, Chugai - Consulting fees, Wyeth - Consulting fees. T.S., Roche -
Stocks or Stock options, Employment. P.P.T., Roche - Research
grants, Consulting fees, Merck-Serono - Research grants Genentech -
Consulting fees. H.T., Roche - Employment. R.F.vV., Roche -
Consulting fees, Research grants, Abbott - Research grants,
Schering Plough - Research grants, UCB - Consulting fees, Wyeth -
Consulting fees. All other authors have declared no conflicts of interest.
Placeboþ
MTX
Rituximab
(2 500 mg) þ
MTX
Rituximab
(2 1000 mg)þ
MTX
Radiological outcome at
52 weeks
n¼232 n¼ 239 n¼ 244
Mean change in mTSS 1.079 0.646 0.359
Patients with change in
mTSS 0 (%)
53.4 57.7 63.5
Clinical outcome at 52 weeks n¼249 n¼ 249 n¼ 250
ACR20 (%) 64.3 76.7 80.0
ACR50 (%) 41.8 59.4 64.8
ACR70 (%) 24.9 42.2 46.8
ACR90 (%) 9.2 17.3 16.4
Major clinical response (%) 8.0 17.3 18.4
EULAR response (%) 71.1 82.3 86.0
DAS remission (%) 12.6 25.4 30.5
Mean change in DAS28 n¼244
-2.06
n¼ 247
-3.05
n¼ 248
-3.21
P< 0.05, P< 0.001, P< 0.0001 compared with placeboþMTX
OP7. AN ASSESSMENT OF THE SERIOUS INFECTION RATE
IN RITUXIMAB-TREATED RHEUMATOID ARTHRITIS (RA)
PATIENTS WHO SUBSEQUENTLY RECEIVED OTHER
BIOLOGIC THERAPIES: A FOLLOW-UP FROM RITUXIMAB
CLINICAL TRIALS
Mark C. Genovese1, Ferdinand C. Breedveld2, Paul Emery3, Stanley
B. Cohen4, Edward C. Keystone5, Eric L. Matteson6, Laura
S. Burke7, Akiko Chai8, William G. Reiss9, Marianne T. Sweetser10
and Tim M. Shaw11
1Immunol-Rheumatol, Stanford University, Palo Alto, CA, USA;
2Rheumatology, Leiden University, Leiden, Netherlands;
3Musculoskel Dis, Chapel Allerton Hospital, Leeds, UK;
4Rheumatology, Metroplex Clin. Res. Center, Dallas, TX, USA;
5Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada;
6Rheumatology, Mayo Clinic, Rochester, MN, USA; 7Medical
Science, Roche Inc., Welwyn Garden City, UK; 8Biostatistics,
Genentech, South San Francisco, CA, USA; 9Clinical Dev,
Genentech, South San Francisco, CA, USA; 10Drug Safety, Biogen
Idec, Cambridge, MA, USA; 11Clin. Sci. Inflamm, Roche Ltd., Welwyn
Garden City, UK
Background: As the pharmacodynamic effect of rituximab may be
long lasting, this analysis was conducted to describe the rate of
serious infection events (SIEs) in patients with RA previously treated
with rituximab and subsequently receiving a biologic disease-modify-
ing antirheumatic drug (DMARD) while peripherally B cell (CD20þ)
depleted.
Methods: Patients with moderately to severely active RA receiving
rituximab plus methotrexate who withdrew or exited from clinical
studies entered a safety follow-up (SFU) period. During SFU,
peripheral B cell counts were monitored at regular intervals for  48
weeks and patients were permitted to receive other biologics. SIEs
were recorded throughout the SFU.
Results: As of April 2008, 2579 RA patients had received  1 rituximab
course, which amounted to 5964.3 patient-years (pt-yrs) of follow-up.
Overall SIE rate was 4.26 (95% CI: 3.77, 4.92) per 100 pt-yrs. Of
patients who entered the SFU, 216 were subsequently treated with
another biologic; most (n¼178) received a TNF inhibitor (TNFi:
etanercept, infliximab or adalimumab) after rituximab for 191.72 pt-
yrs, whereas others received abatacept (n¼ 31, 19.25 pt-yrs) or
anakinra (n¼9). Median follow-up after receipt of the subsequent
biologic was 11 months (range: 0–45). For the majority of patients
(86.1%), peripheral B cell CD19 levels were depleted below the lower
limit of normal at the time of receiving their subsequent biologic. About
35% of patients received their biologic within 6 months of their last
rituximab infusion. Median time to the SIE after initiating biologic
therapy was 6 months (range: 0–23). In the 31 patients receiving
abatacept and the nine patients receiving anakinra, there was one SIE
before and one SIE after receiving each of these biologics. Serious
infections were typical for RA patients with no opportunistic or fatal
infections.
Conclusions: The use of other biologics in RA patients previously
treated with rituximab was not associated with an increase in rate of
SIEs in patients who received biologics or in the subgroup who
received a TNFi.
Disclosure statement: F.C.B., Roche - Consulting fees. L.S.B.,
Roche - Employment. A.C., Genentech - Employment. S.B.C.,
Roche - Research grant, Consulting fees, Bioden-Idec - Research
grant, Consulting fees, Genetech - Research grant, Consulting fees.
P.E., Roche - Research grants, Consulting fees, Abbott - Research
grants. M.C.G., Biogen-Idec - Research grant, Consulting fees,
Genentech - Research grant, Consulting fees, Roche - Research
grant. E.C.K., Amgen - Research grants, Consulting fees, Schering-
Plough - Research grants, Consulting fees, Abbott - Consulting fees,
Speakers bureau, Roche - Consulting fees, BMS - Consulting fees,
Centocor Inc - Consulting fees, Genentech - Consulting fees,
Wyeth - Consulting fees. E.L.M., Amgen - Research grant, Centocor
- Research grant, Biogen Idec - Research grant, Abbott - Research
grant, Genentec - Research grant. W.G.R., Genentech - Employment.
T.M.S., Roche - Stocks or Stock options, employment. M.T.S., Biogen
Idec - Stock and stock options, employment.
SIEs in patients receiving biologic DMARDs
following rituximab treatment
Other biologic post rituximab TNFi post rituximab
Before biologic After biologic Before TNFi After TNFi
Exposure, pt-yrs 227.00 224.00 183.58 191.72
No. of SIEs 13 12 11 10
SIE rate (95% CI),
per 100 pt-yrs
5.73
(3.33, 9.86)
5.36
(3.04, 9.43)
5.99
(3.32, 10.82)
5.22
(2.81, 9.69)
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OP8. GENETIC POLYMORPHISMS IN KEY METHOTREXATE
PATHWAY GENES ASSOCIATED WITH RESPONSE TO MTX
TREATMENT IN RHEUMATOID ARTHRITIS
Sally A. Owen1, Stephen Eyre1, Paul Martin1, Samantha Hider2, Ian
N. Bruce1, Anne Barton1 and Wendy Thomson1
1arc-Epidemiology Unit, The University of Manchester, Manchester,
UK; 2arc National Primary Care Centre, Keele University,
Staffordshire, UK
Background: Methotrexate (MTX) is the cornerstone of treatment for
rheumatoid arthritis (RA). However, up to a third of individuals will fail
to respond to MTX treatment or suffer adverse events (AE). The main
determinates of MTX response in RA remain unclear, although
evidence suggests that part of this variability is genetic. Genes
within the MTX metabolic pathway represent good candidates as
predictors of response. We investigated SNPs spanning 11 MTX
pathway genes on the efficacy and occurrence of AE in MTX treated
patients with RA.
Methods: Subjects included 309 RA patients with a defined response
to MTX. Patients were included if they were (i) good responders
(n¼ 147) (with an ESR <20 and/or normal CRP and on a stable dose of
MTX for at least 6 months) (ii) inefficacy failures (n¼ 101) (physician
statement and failure to reduce ESR/CRP by 20%) or (iii) AE failures
(n¼ 61) (verified by medical record review). Tagging SNPs were
selected for genes: AMPD1, ATIC, DHFR, FPGS, GGH, ITPA,
MTHFD1, MTHFR, SHMT1, SLC19A1 (RFC) and TYMS using an r2
cutoff0.8 and MAF 0.05 within 10kb up and down stream of each
gene. Genotyping was performed using the Sequenom iPlex
MassARRAY platform. Three different analyses were conducted: 1)
responders vs inefficacy failures 2) responders vs AE failures and 3)
responders vs inefficacy and AE failures combined. Genotype
frequencies were compared between the groups using the trend test
implemented in PLINK and allelic odds ratios with 95 % CIs (CI)
calculated in STATA 9.2.
Results: Of the 150 SNPs tested, nine were found to be significantly
associated (p-trend 0.05) with MTX response and two with MTX
related AE. Interestingly three of these (rs12995526, rs7563206 and
rs16853834) were found in the 5-aminoimidazole-4-carboxamide
ribonucleotide transformylase (ATIC) gene, which encodes an
enzyme that is important in the de novo purine synthesis pathway.
Individuals carrying these SNPs had an increased risk of poor
response to MTX (OR 1.48, 95% CI (1.01-2.17), OR 1.47, 95% CI
(1.00-2.17) and OR 1.47 95% CI (1.01-2.76). Other associations
included 6 SNPs in the SLC19A1 gene (rs11702425, rs2838956,
rs7499, rs2274808, rs9977268, rs7279445) all conferring an increased
risk of poor response to MTX and two SNPs in the DHFR gene
(rs12517451, rs10072026) were associated with AE. In addition there
were a further two SNPs in the FPGS gene associated with AE under a
recessive model (rs1054774, rs4451422) and one additional SNP in the
ATIC gene approaching statistical significance (rs4673990) (p-
trend<0.1) warranting further investigation.
Conclusions: Genetic variations in a number of key MTX pathway
genes have been found to be significantly associated with MTX
response and AE in RA patients. Further studies will be required to
validate these findings. If confirmed these results could contribute
towards a better understanding of and ability to predict MTX response
in RA.
Disclosure statement: All authors have declared no conflicts of
interest.
OP9. A COMPARISION OF TOCILIZUMAB (TCZ) AND
METHOTREXATE (MTX) MONOTHERAPIES IN MTX- OR
DMARD-NAI¨VE PATIENTS WITH RHEUMATOID
ARTHRITIS (RA)
G. Jones1, J. J. Gomez-Reino2, M. B. Lowenstein3, J. Tornero4,
A. Sebba5, E. Alecock6, E. Guarin7 and M. Genovese8
1Menzies Research Institute, University of Tasmania, Hobart, TAS,
Australia; 2Universidad de Santiago de Compostela, Santiago de
Compostela, Spain; 3Arthritis Center, Palm Harbour, FL, USA;
4Hospital General Universitario de Guadelajara, Guadelajara, Spain;
5University of South Florida, Palm Harbour, FL, USA; 6F. Hoffmann-
La Roche, Welwyn, UK; 7F. Hoffmann-La Roche, Basel, Switzerland;
8Stanford University Medical center, Palo Alto, CA, USA
Background: In the AMBITION study, TCZ monotherapy demon-
strated clinical superiority over MTX monotherapy in patients with
active RA who had not previously failed MTX or biologic treatment,
with a well-defined and manageable safety profile. The aim of this
analysis was to compare the efficacy of TCZ and MTX monotherapies
in MTX-naı¨ve and disease-modifying anti-rheumatic drug (DMARD)-
naı¨ve patients with RA from AMBITION.
Methods: This study was a post hoc analysis from the AMBITION
study, in which patients (N¼570, intent-to-treat [ITT] population) were
randomized to one of two treatment arms for 24 weeks: intravenous
TCZ 8 mg/kg every 4 weeks or an initial dose of MTX 7.5 mg/week
titrated up to 20 mg/week within 8 weeks. Previous exposure to MTX
was allowed in this study, but not within 6 months prior to study entry
and patients could not have failed previous MTX, other DMARDs or
biological therapy. For this analysis, MTX-naı¨ve patients were defined
as never having been exposed to MTX and DMARD-naı¨ve patients as
never having been exposed to MTX or any traditional DMARD; patients
in these groups were not mutually exclusive. ACR20, ACR50 and
ACR70 responses, DAS28 remission (DAS28<2.6) and EULAR good
response efficacy parameters were assessed at 24 weeks for the ITT
population and the MTX- and DMARD-naı¨ve patients of the AMBITION
study.
Results: In the ITT population, 67% of patients were MTX naı¨ve and
43% were DMARD naı¨ve. Baseline demographics and RA character-
istics (rheumatoid factor positive, steroid use, DAS28) of MTX- and
DMARD-naı¨ve patients were well balanced between treatment groups
and consistent with the ITT population; of note, RA duration was shorter
in MTX- and DMARD-naı¨ve vs the ITT population. Post hoc analysis
showed that patients in the MTX- and DMARD-naı¨ve populations
achieved efficacy responses comparable with those in corresponding
treatment groups of the ITT population at 24 weeks (Table), with a
suggestion that these relatively treatment-naı¨ve patients had higher
response rates. In all populations, TCZ 8 mg/kg was superior to MTX
(mean dose 15.5 mg/week) across all outcomes measured.
Conclusions: TCZ monotherapy was superior to MTX monotherapy
after 24 weeks of treatment for RA regardless of the patient’s previous
exposure to MTX or DMARDs.
Disclosure statement: E.A., F. Hoffmann-La Roche - Employee.
M.G., F. Hoffmann-La Roche - Honoraria, Research funding. E.G., F.
Hoffmann-La Roche - Employee. G.J., F. Hoffmann-La Roche -
Honoraria, Research Funding. All other authors have declared no
conflicts of interest.
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OP10. PERCUTANEOUS ENDOSCOPIC GASTROSTOMY
(PEG) FEEDING: A LIFE-SAVING INTERVENTION IN SYSTEMIC
SCLEROSIS-MYOSITIS OVERLAP WITH PHARYNGEAL
DYSFUNCTION
Leena Das1, Andrew Bowden2, Robert G. Cooper1, William Mitchell3,
Margaret O’Sullivan4 and Ariane L. Herrick1
1Rheumatology, Salford Royal NHS Foundation Trust, Salford, UK;
2Rheumatology, Rochdale Royal Infirmary, Rochdale, UK;
3Rheumatology, Furness General Hospital, Barrow-In-Furness, UK;
4Rheumatology, North East Wales NHS Trust, Wrexham, UK
Background: Although dysphagia in patients with systemic sclerosis
(SSc) is usually due to lower oesophageal dysmotility, oropharyngeal
dysphagia can also occur, especially in patients with myositis overlap.
Here we describe 3 patients with SSc and pharyngeal dysphagia, all of
Efficacy parameters at 24 weeks for the ITT population and the MTX- and DMARD-naı¨ve patients of the AMBITION study
Response rates
at 24 weeks, n (%)
MTX (ITT)
(n¼ 284)
TCZ (ITT)
(n¼ 286)
MTX (MTX naı¨ve)
(n¼190)
TCZ (MTX naı¨ve)
(n¼ 191)
MTX (DMARD naı¨ve)
(n¼ 129)
TCZ (DMARD naı¨ve)
(n¼115)
ACR20 149 (52.5) 200 (69.9) 102 (53.7) 131 (68.6) 67 (51.9) 78 (67.8)
ACR50 95 (33.5) 126 (44.1) 63 (33.2) 86 (45.0) 42 (32.6) 56 (48.7)
ACR70 43 (15.1) 80 (28.0) 27 (14.2) 52 (27.2) 19 (14.7) 37 (32.2)
EULAR good response 48 (16.9) 115 (40.2) 32 (16.8) 84 (44.0) 23 (17.8) 55 (47.8)
(n¼ 248)y (n¼ 253)y (n¼166)y (n¼ 170)y (n¼ 109)y (n¼98)y
DAS28 remission 30 (12.1) 85 (33.6) 22 (13.3) 58 (34.1) 16 (14.7) 39 (39.8)
P< 0.05 vs MTX; yNo imputation for missing DAS28 remission was performed.
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